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SINCE THE INTRODUCTION of cyclo-
sporine (Cs)-steroid therapy in 1980,665 
patients received orthotopic liver transplanta-
tion by the end of June 1986 at the University 
Health Sciences Center of Colorado (in 
1980), the University Health Center of Pitts-
burgh (since 1981), and the Pittsburgh-affil-
iated Baylor University Medical Center of 
Dallas (since 1985). One- to 5-year actuarial 
survival rates of these patients were 70%, 
65%, 62%, 61 %, and 61 %, respectively, as of 
July 31, 1986. With these good survival rates, 
liver transplantation has been accepted as a 
therapeutic modality for end-stage liver dis-
ease, and >50 medical centers worldwide have 
started liver transplantation in the last few 
years. This report summarizes the long-term 
mortality and morbidity after liver transplan-
tation to provide some useful guides in manag-
ing liver recipients after the first posttrans-
plant year. 
CASE MATERIAL AND METHOD 
During the 5-year period between 1980 and 1984, 313 
patients received orthotopic liver transplantation under 
Cs-steroid therapy at the University Health Sciences 
Center of Colorado (I4 patients in 1980) and at the 
University Health Center of Pittsburgh (299 patients 
between 1981 and 1984). Two hundred sixteen (69%) of 
the 313 patients survived at least I year after transplant. 
Medical records of these 216 I-year survivors are 
reviewed to study late mortality and morbidity. The 
follow-up period ranged from 18 months to 75 months 
with a median follow-up of 30 months as of June 30, 
1986. 
The age of patients ranged from 7 months to 54 years. 
Ninety-six patients were aged <18 years, and 120 
patients were > 18 years. The three most common liver 
diseases among pediatric recipients were biliary atresia, 
inborn errors of metabolism (a-I-antitrypsin deficiency 
disease, Wilson's disease, tyrosinemia, etc.), and postne-
crotic cirrhosis; those most common in adult recipients 
were post necrotic cirrhosis, primary biliary cirrhosis, and 
sclerosing cholangitis. 
Survival rates were calculated by life-table analysis of 
Kaplan-Meyer. The I-year survival rate was actual and 
2- to 5-year survival rates were actuarial figures. 
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RESULTS 
Survival After Liver Transplantation 
The I-year survival rate of 313 patients 
who received liver transplantation between 
1980 and 1984 was 69%; and 2- to 5-year 
survival rates were 64%, 62%, 60% and 60%, 
respectively, as shown in Fig I. Survival rates 
of the 216 I-year survivors after the first year 
were 93%, 90%, 87%, and 87%, respectively, 
at 2 to 5 years after transplant, as shown in 
Fig 2. Thus, the chance of dying between 1 
and 5 years after liver transplant was only 
13% of I-year survivors. 
Deaths> 1 Year After Liver Transplantation 
Thirteen patients died between I and 2 
years after liver transplantation. Four patients 
died of recurrence of primary liver malig-
nancy (one example each of epithelioid 
hemangioendothelioma, hepatocellular carci-
noma, cholangiocarcinoma, and bile duct car-
cinoma). A fifth patient died of myocardial 
infarction with recurrence of hepatocellular 
carcinoma. Another patient died of dissemi-
nated oat cell cancer of the lung diagnosed> I 
year after transplant. Thus, 6 of the 13 deaths 
were caused by or related to cancer. 
Two of the other seven deaths were due to 
liver failure caused by graft rejection after 
retransplantation. Another patient died of 
septicemia following chemotherapy for mye-
loproliferative disorder that caused recurrent 
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Budd-Chiari syndrome. Single deaths were 
caused by liver failure due to recurrent hepati-
tis B and septicemia, recurrent pancreatitis 
and abdominal abscess, gastrointestinal 
bleeding and liver failure due to rethrombosis 
of the portal vein, seizures of undetermined 
cause, and cardiopulmonary arrest. 
Between 2 and 3 years after transplanta-
tion, 4 patients died: I of recurrence of fibro-
lamellar hepatocellular carcinoma, 1 of liver 
failure due to rejection, and 2 of graft rejec-
tion and infectious complications 4 months 
and 8 months, respectively, following retrans-
plantation for primary graft failure. 
Two patients died between 3 and 4 years 
after transplant. One patient died of graft 
failure due to rejection; the second patient 
died of lymphoma and aspergillosis. The diag-
nosis of lymphoma was unduly delayed for 
several months. 
There has been no death after 4 years-as of 
June 3D, 1986. 
Rejection and Retransplantation >1 Year 
After Liver Transplantation 
Twenty-five of the 216 I-year survivors 
experienced moderate to severe graft rejection 
> 1 year after liver transplantation. Rejection 
episodes of 18 patients occurred between 1 
and 2 years after transplant, those of 5 
patients occurred between 2 and 3 years, and 
those of 2 patients occurred between 3 and 4 
years. 
;' 
LIVER TRANSPLANT -LONG-TERM FOLLOW-UP 
Two of the 25 patients died from graft liver 
failure before retransplantation could be per-
formed. Eleven of the 25 patients underwent 
transplantation-8 after 1 to 2 years, and 3 
between 2 and 3 years. Four of the 11 died 
after retransplantation. The deaths occurred 
intraoperatively 2 weeks later because of liver 
graft failure, 4 months later because of sys-
temic herpes virus infection, and 8 months 
later because of graft failure and bacterial 
and fungal infection. Seven of the 11 patients 
who received retransplantation > I year after 
the initial grafting were alive from 4 months 
to >3 years after retransplantation as of June 
30, 1986. 
Of the 25 patients who underwent late 
rejection, the remaining 12 still have their 
original grafts. The liver function tests of 
seven patients have returned to normal or near 
normal after antirejection therapy. These 
tests have improved but remain abnormal in 
four patients, and they are worsening in one 
patient who is waiting for retransplantation. 
Posttransplant Malignancy 
Six of the 216 I-year survivors developed de 
novo malignancy > 1 year after liver trans-
plantation. Five of the six patients developed 
posttransplant lymphoma or Iymphoprolifera-
tive lesions, and another patient developed oat 
cell cancer of the lung. Two of the six patients 
died from malignancy as previously described: 
one from lymphoma in the fourth year and 
another from lung cancer in the second year 
posttransplantation. The remaining four pa-
tients who developed lymphoma in the second 
year have been cured of lymphoma by drastic 
reduction or temporary discontinuation of 
immunosuppression therapy; and they all 
were alive with good liver function as of June 
30,1986. 
Late Bile Duct Complication 
Seven surgically corrected biliary duct 
strictures occurred among 216 I-year survi-
vors. Five of the seven biliary strictures devel-
oped after end-to-end choledochocholedo-
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chostomy, and two developed after end-to-side 
choledochojejunostomy in Roux-en-y. None 
of the strictures after choledochocholedochos-
tomies occurred at the anastomosis. Three of 
the five choledochocholedochostomies were 
strictured at the recipient distal common duct, 
and two of them were strictured at the donor 
hepatic duct just below the bifurcation. All 
five strictures were corrected by hepaticojeju-
nostomy in Roux-en-y I to 6 years after 
transplant. Two choledochojejunostomies 
were strictu red at the anastomosis and were 
corrected by revision of the anastomosis in the 
second and fourth posttransplant year. 
Two other patients had surgically uncor-
rectable intrahepatic biliary strictures similar 
to those of primary sclerosing cholangitis. 
These strictures were successfuIIy treated by 
transhepatic biliary catheter and balloon dila-
tation, but both patients were suffering from 
occasional bouts of cholangitis. 
Renal Impairment 
Serum creatinine levels of 120 adult (aged 
> 18 years) I-year survivors were 1.7 ± 0.5, 
1.7 ± 0.5, 1.8 ± 0.6, 1.6 ± 0.5, and 1.3 ± 0.5 
mg/dL (mean ± SD), respectively, at I to 5 
years after liver transplantation; those of 96 
pediatric I-year survivors were 0.7 ± 0.3, 
0.7 ± 0.3; 0.7 ± 0.3,0.8 ± 0.5, and 0.8 ± 0.4 
mg/dL (mean ± SD), respectively, at 1 to 5 
years. Only 6 adult recipients had serum 
creatinine levels that remained persistently 
>2.0 mg/dL, and only 3 pediatric recipients 
had creatinines levels that remained > 1.0 
mg/dL during I to 6 years of follow-up. No 
patients required chronic maintenance dialy-
sis after liver transplantation; in two patients, 
however, Cs had to be discontinued because of 
nephrotoxicity of the drug; azathioprine 
(Aza) was substituted. 
Other Major Complications 
Seventeen other nonfatal major complica-
tions developed in 15 of the 216 I-year survi-
vors 1 to 4 years after liver transplantation. 
Eight of the 17 complications were infectious: 
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2 bacteremia due to urinary tract infection, 1 
toxic shock syndrome caused by Staphylococ-
cus pneumoniae in a splenectomized child, 1 
Candida brain abscess, one cryptococcal 
meningitis, 1 acute gangrenous appendicitis, 1 
acute pancreatitis associated with Epstein-
Barr virus infection, and I non-A, non-B acute 
viral hepatitis. Two patients developed 
orthopedic complications, one of which was a 
tibial fracture that occurred when the patient 
fell. The other was aseptic necrosis of the hip, 
which required a prosthesis. Two major gas-
trointestinal hemorrhages occurred: one 
caused by a gastric ulcer that was successfully 
managed medically, and another caused by 
esophageal varices due to portal vein throm-
bosis that was successfully treated by distal 
splenorenal shunt. One patient developed 
hypertensive crisis with a systolic pressure 
>200 mm Hg. The patient's hypertension was 
finally controlled after discontinuation of Cs. 
The last complication was idiopathic throm-
bocytopenic purpura which developed during 
the fourth posttransplant year. The platelet 
depression was refractory to steroid therapy 
and was successfully treated by splenectomy. 
DISCUSSION 
Since the introduction of Cs for clinical 
transplantation, survival rates after liver 
transplantation have improved to I-year sur-
vival of 70% and 5-year survival of 60%.1 Our 
long-term follow-up of 216 I-year survivors 
showed that the chance of dying each year 
after the first year was <3% when the deaths 
from recurrent hepatic malignancy were 
excluded. 
The most common cause of death after the 
first year was late graft failure due to rejec-
tion before or after retransplantation. There-
fore, continuous monitoring of liver function is 
essential for long-term survival. We usually 
obtain a monthly checkup in the second year 
and every 2 to 3 months thereafter. Closer 
follow-up is necessary when immunosupres-
sive therapy is changed or liver function tests 
become abnormal. 
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The second most common cause of death 
was recurrent hepatic malignancy. More than 
two-thirds of patients who received liver 
transplantation for the treatment of conven-
tionally unresectable hepatic malignancy died 
from recurrence within two years. 2 To prevent 
tumor recurrence, we recently instituted adju-
vant chemotherapy soon after successful liver 
transplantation for patients whose indication 
for transplant was hepatic malignancy. 
Six patients developed new malignant 
tumors > 1 year after liver transplantation. 
Five of the six malignancies were lymphomas 
or lymphoproliferative lesions related to 
immunosuppression and viral infection as prJ, 
viously reported.3 We believe that the lympho-
mas developed after transplantation are 
almost always induced by immunosuppression 
therapy and viral infection such as Epstein-
Barr virus and that the treatment of choice is 
drastic reduction of immunosuppression 
rather than cytotoxic chemotherapy.3 Four of 
the five patients with lymphoma so treated are 
alive and well with good liver function. Only 
one patient, whose diagnosis of lymphoma had 
been delayed for several months, died of dis-
seminated lymphoma and aspergillosis in the 
fourth year. Another patient developed dis-
seminated oat cell cancer of the lung and died 
in the second year. 
Although most bile duct complications are 
identified within the first 6 months of trans-
plant,4 surgically correctable bile duct compli-
cation can occur late after liver transplanta-
tion in patients whose clinical course has been 
stable over years. Clinical manifestation of 
late bile duct complications are often atypical 
for bile duct stricture and cholangitis; further-
more, laboratory abnormalities are similar to 
those of graft rejection. A high index of suspi-
cion is important if abnormal liver function 
tests that are unresponsive to anti rejection 
therapy develop. Although histological evi-
dence of mild graft rejection may be present, 
direct visualization of the biliary system may 
identify partial bile duct obstruction. Liver 
biopsy and ultrasonography have not been 
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accurate in diagnosing late bile duct compli-
cations in our experience. After partial biliary 
obstruction was relieved, liver function tests of 
all seven patients with late reintervention 
returned to normal. 
The etiology of intrahepatic biliary stric-
ture in our two patients is unknown. Four 
others developed this peculiar biliary stricture 
within the first 12 months after liver trans-
plantation. All these patients had had moder-
ate to severe graft rejection prior to the devel-
opment of intrahepatic biliary strictures. It is 
possible that intrahepatic biliary stricture 
within liver grafts is either the result or a form 
of graft rejection. 
The nephrotoxicity of Cs must be sur-
mounted to maintain good liver graft function 
chronically. Although we have not yet used 
chronic maintenance dialysis in our liver 
recipients, Cs had to be withdrawn and substi-
tuted by Aza in two patients. With careful 
adjustment of dosage, Cs can be used as a 
maintenance immunosuppressive agent for at 
least 5 years without causing clinically signifi-
cant renal impairment in most patients. 
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After 1 year, infectious complications occur 
less frequently than during the first year. 
Orthopedic complications such as aseptic 
necrosis are rare in long-term survivors, prob-
ably because maintenance steroid doses are 
significantly lower with Cs than those previ-
ously commonly used with Aza. Life after a 
year of liver transplantation has been quite 
satisfactory for most of the recipients and 
>85% of I-year survivors are expected to live 
at least 5 years. The quality of life in chronic 
survivors has greatly improved since the issue 
was last formally examined at this same meet-
ing 8 years ago.s 
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